Tech Company Financing Transactions
GenrAb Funding Round
GenrAb closed a $5.6 million Seed investment round on 4/22/2025. Backers included Actium Group.
Transaction Overview
Company Name
Announced On
4/22/2025
Transaction Type
Venture Equity
Amount
$5,600,000
Round
Seed
Investors
Actium Group (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate the development of its lead candidate, TGM-010, a new, fully-human, neuroprotective antibody.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
BioLabs Pegasus Park 3060 Pegasus Park Dr Building 6
Dallas, TX 75247
USA
Dallas, TX 75247
USA
Phone
Undisclosed
Website
Email Address
Overview
Neurodegeneration is the process of slow neuronal death that is at the core of diseases such as ALS, Parkinson's, Alzheimer's and even Multiple Sclerosis. GenrAb is harnessing the power of the human immune system to develop therapies that can protect and treat patients with neurological disease. Developing neuroprotective agents will provide patients the next generation of treatment that can prevent the progression of disease and allow for new approaches to their care.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Larry Tiffany
Chief Financial Officer
Rich Vincent
Chief Marketing Officer
Benjamin Greenberg
Chief Operating Officer
Martin Devenport
Browse more venture capital transactions:
Prev: 4/22/2025: Tella HQ venture capital transaction
Next: 4/22/2025: Ocient venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions reported here come from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs